The MEA Anti-infective agents market was valued at US$ 8,188.65 million in 2022 and is projected to reach US$ 9,512.24 million by 2028.
It is expected to grow at a CAGR of 2.5% during the forecast period.
Rising investments in R&D activities in the pharmaceutical sector is the major factor driving the growth of the Middle East & Africa anti-infective agents market. Anti-infective discovery strategies are currently concentrated on two approaches: The development of antibiotic adjuvants for combined therapy with the existing antibiotics in clinical use and the discovery of small molecules with new mechanisms of action that can disable unexplored objectives for bacterial survival. A few of the novel approaches used primarily focused on improving existing drugs. Gram-negative ESKAPE pathogens, such as Pseudomonas aeruginosa and Enterobacteriaceae, which the WHO named in 2017 as the top priority pathogens for developing novel anti-infective therapies, are known for causing multi-resistant healthcare-associated infections. Nevertheless, despite the difficulties and the expense, the creation of chemicals with novel modes of action has the potential to improve the capacity to manage microorganisms for treatments significantly. The anticipated revenue from a new drug, the anticipated development costs, and laws that affect drug supply and demand all have a role in determining how much money pharmaceutical companies invest in research and development.
The increasing investment in the pharmaceutical industry is boosting the demand for anti-infective agents. Therefore, the increasing investment in the pharmaceutical industry is expected to contribute significantly to the anti-infective agents market during the forecast period.
Vendors can attract new customers and expand their footprints in emerging markets with new features and technologies. This factor is likely to drive the Middle East & Africa anti-infective agents market at a good CAGR during the forecast period.
It is expected to grow at a CAGR of 2.5% during the forecast period.
Rising investments in R&D activities in the pharmaceutical sector is the major factor driving the growth of the Middle East & Africa anti-infective agents market. Anti-infective discovery strategies are currently concentrated on two approaches: The development of antibiotic adjuvants for combined therapy with the existing antibiotics in clinical use and the discovery of small molecules with new mechanisms of action that can disable unexplored objectives for bacterial survival. A few of the novel approaches used primarily focused on improving existing drugs. Gram-negative ESKAPE pathogens, such as Pseudomonas aeruginosa and Enterobacteriaceae, which the WHO named in 2017 as the top priority pathogens for developing novel anti-infective therapies, are known for causing multi-resistant healthcare-associated infections. Nevertheless, despite the difficulties and the expense, the creation of chemicals with novel modes of action has the potential to improve the capacity to manage microorganisms for treatments significantly. The anticipated revenue from a new drug, the anticipated development costs, and laws that affect drug supply and demand all have a role in determining how much money pharmaceutical companies invest in research and development.
The increasing investment in the pharmaceutical industry is boosting the demand for anti-infective agents. Therefore, the increasing investment in the pharmaceutical industry is expected to contribute significantly to the anti-infective agents market during the forecast period.
Vendors can attract new customers and expand their footprints in emerging markets with new features and technologies. This factor is likely to drive the Middle East & Africa anti-infective agents market at a good CAGR during the forecast period.
Middle East & Africa Anti-Infective Agents Market Segmentation
The Middle East & Africa anti-infective agents market is segmented based on type, range, route of administration, indication, distribution channel, and country.- Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment is expected to account for the largest market share by the end of 2022.
- Based on range, the market is segmented into broad spectrum and narrow spectrum. By the end of 2022, the narrow spectrum segment will likely hold a larger market share.
- Based on route of administration, the market is segmented into topical, oral, IV, and others. By the end of 2022, the IV segment is likely to hold the largest market share.
- Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. In 2022, the others segment is projected to hold the largest share of the market.
- Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. By the end of 2022, the hospital pharmacies segment is likely to hold the largest market share.
- Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. The Rest of the MEA is expected to hold the largest market share by the end of 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. MEA Anti-infective agents Market - Market Landscape
5. MEA Anti-Infectives Agents Market - Key Market Dynamics
6. Anti-Infectives Agents Market - MEA Analysis
7. MEA Anti-Infectives Agents Market Analysis and Forecast to 2028 - Type
8. MEA Anti-Infectives Agents Market Analysis and Forecast to 2028 - Range
9. MEA Anti-Infectives Agents Market Analysis and Forecast to 2028 - Route of Administration
10. MEA Anti-Infectives Agents Market Analysis and Forecast to 2028 - Indication
11. MEA Anti-Infectives Agents Market Analysis and Forecast to 2028 - Distribution Channel
12. MEA Anti-Infectives Agents Market Analysis and Forecasts to 2028 - Country Analysis
13. Anti-infectives Agents Market-Industry Landscape
14. Anti-Infectives Agents Market- Company Profiles
15. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott
- Allergan Plc.
- Astellas Pharma Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Novartis AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 8188.65 Million |
| Forecasted Market Value ( USD | $ 9512.24 Million |
| Compound Annual Growth Rate | 2.5% |
| Regions Covered | Africa, Middle East |
